SARS-related warning letter
This article was originally published in The Tan Sheet
Executive Summary
FDA issued a warning letter for claims that BetaLoe Immune System Defense Supplement provides "protection for defense against flu, SARS and anthrax," in addition to statements alluding to diseases. Statements include: "Why would a person want to use BetaLoe? Look around you...SARS outbreaks, deadly flu outbreaks, anthrax threats..." The agency says the claims render the product a drug, which requires an NDA...
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.